# Contact NXT LVL Peptides — Editorial Desk

> Reach the NXT LVL Peptides editorial desk regarding citations, corrections, or research-related correspondence about our Growth Hormone Axis peptide digest.

Corrections, new trial data, and citation questions — the messages this desk is built to receive.

## Editorial correspondence

NXT LVL Peptides tracks corrections and updates on CJC-1295, CJC-1295 / Ipamorelin, and tesamorelin: a citation stated inaccurately, a newly published trial, a regulatory status change, or a source that should appear on the [references page](/references). This is the most useful class of message this desk receives.

The most actionable submissions name the page, the exact passage in question, and a supporting source — a DOI or PubMed identifier where possible. That format lets a proposed change be checked against its source before anything is edited.

**Editorial mailbox:** editors@nxtlvlpeptides.com

## What this desk cannot do

NXT LVL Peptides is a literature digest, not a clinical service or a vendor. It cannot advise on human use of any compound discussed here, recommend a dose or schedule, evaluate whether a cited trial applies to a specific person, or help locate, source, or purchase any compound from any supplier.

Tesamorelin is a prescription medicine available only through a licensed provider, for its approved indication. CJC-1295 and CJC-1295 / Ipamorelin are unapproved research chemicals; this desk does not advise on their acquisition or use. Readers subject to anti-doping rules should note that all three compounds fall under WADA's peptide-hormone restrictions. Editorial responses are not guaranteed and may be delayed.

---

A research digest on GH-axis peptides — it reports what the studies show, and stops there. No clinic. No sourcing.